Evidence – Marijuana Effective for Pain Control & Can Limit Opiate Abuse

What if I tell you that there is no good evidence that marijuana does any good for treating glaucoma, anxiety, or Parkinson's disease. Despite this, it is often prescribed to treat these aliments in states that have legalized marijuana. According to a large meta analysis of 79 studies published in Journal of the American Medical Association marijuana does nothing to improve these diseases. However, this analysis did show that there is excellent evidence that marijuana is highly effective in controlling chronic pain. A JAMA review found a  "30% or greater improvement in pain with cannabinoid compared with placebo," across the [...]

Prostate Cancer drugs cost more in the USA than in other countries.

The cost of Enzalutamide (Xtandi) in the United States is being challenged by Knowledge Ecology International (KEI), a public interest advocacy group.  The average US wholesale price of Xtandi in 2015 was $88 per capsule.   That can add up to $129,000 annual cost per man. There are significant issues related to high costs of treatment. The higher the cost, the more likely that insurance companies will  require pre-authorization to cover the cost of the drug.  That means a man dealing with advanced stage disease is tasked with asking his doctor to spend uncompensated time fighting the insurance company for his [...]

Of Interest In the News – Surprise Out-of Network Bills and the U.S. Preventive Task Force Becomes Controversial

In an article in Time (3/7 Sweetland Edwards) there is a discussion about the failure of the Affordable Care Act to stop patients from receiving “surprise” bills from their medical providers for services provided. These surprises result from people going to a medical facility, which is in their Network but having some service, provided by an individual provider who is outside their network. This type of problem often results from the use of out of network labs and anesthesiologists who just show up and provide a service without the informed consent of the patient and the knowledge of the patient. [...]

By | March 9th, 2016|Insurance, Politics of Cancer, Uncategorized, USPTF|0 Comments

NICE Recommends Xtandi, but Not Zytiga in the Pre-Chemotherapy Stage of Advanced Prostate Cancer Treatment

NICE, which serves as a cost-effectiveness agency has said in a draft guidance that it supports the use of Xtandi (enzalutamide) in men whose prostate cancer has spread after the failure of first-line therapy (i.e. ADT), but for whom chemotherapy is not yet necessary. The agency found that Xtandi can delay the need for chemotherapy, is well tolerated, and improves survival.  After their review they have determined that Xtandi is an appropriate use of NHS resources, with an incremental cost-effectiveness ration of £34,500 compared to best supportive care. On the other hand NICE was less impressed with Johnson & Johnson's [...]

スーパーコピーブランド ロレックススーパーコピー オメガスーパーコピー ブルガリスーパーコピー ブライトリングスーパーコピー カルティエスーパーコピー シャネル時計コピー IWCスーパーコピー フランクミュラースーパーコピー パネライスーパーコピー タグホイヤースーパーコピー ウブロスーパーコピー ガガミラノスーパーコピー ルイヴィトンスーパーコピー シャネルスーパーコピー エルメススーパーコピー グッチスーパーコピー ボッテガヴェネタスーパーコピー プラダスーパーコピー セリーヌスーパーコピー ロレックススーパーコピー ウブロスーパーコピー